Cargando…

A2Ar-dependent PD-1+ and TIGIT+ Treg cells have distinct homing requirements to suppress autoimmune uveitis in mice

The proper function of regulatory T cells (Tregs) to suppress inflammation requires homing to the correct tissue site. Resolution of autoimmune uveitis generates distinct programmed death receptor 1 (PD-1(+)) and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peters, Kayleigh, McDonald, Trisha, Muhammad, Fauziyya, Walsh, Marisa, Drenen, Kayla, Montieth, Alyssa, Foster, C. Stephen, Lee, Darren J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512849/ https://www.ncbi.nlm.nih.gov/pubmed/37164238 http://dx.doi.org/10.1016/j.mucimm.2023.04.005

Ejemplares similares

PD-1(+) melanocortin receptor dependent-Treg cells prevent autoimmune disease
por: Muhammad, Fauziyya, et al.
Publicado: (2019)

Combined Deficiency of the Melanocortin 5 Receptor and Adenosine 2A Receptor Unexpectedly Provides Resistance to Autoimmune Disease in a CD8(+) T Cell-Dependent Manner
por: McDonald, Trisha, et al.
Publicado: (2021)

Kallistatin Attenuates Experimental Autoimmune Uveitis by Inhibiting Activation of T Cells
por: Muhammad, Fauziyya, et al.
Publicado: (2020)

Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells
por: Kojima, Marenori, et al.
Publicado: (2023)

TIGIT(+) iTregs elicited by human regulatory macrophages control T cell immunity
por: Riquelme, Paloma, et al.
Publicado: (2018)

MC5r and A2Ar Deficiencies During Experimental Autoimmune Uveitis Identifies Distinct T cell Polarization Programs and a Biphasic Regulatory Response
por: Lee, Darren J., et al.
Publicado: (2016)

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
por: Yue, Chenran, et al.
Publicado: (2022)

Intraocular Implants for the Treatment of Autoimmune Uveitis
por: Lee, Darren J.
Publicado: (2015)

Review of Systemic Immunosuppression for Autoimmune Uveitis
por: Castiblanco, Claudia, et al.
Publicado: (2014)

Coordinated gene expression of Th17- and Treg-associated molecules correlated with resolution of the monophasic experimental autoimmune uveitis
por: Jia, Xiuzhi, et al.
Publicado: (2011)

Progranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1/Th17 Cells and Promoting Treg Cells and M2 Macrophages
por: Wang, Chaokui, et al.
Publicado: (2022)

Microbiome and Autoimmune Uveitis
por: Horai, Reiko, et al.
Publicado: (2019)

TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir
por: Holder, Kayla A., et al.
Publicado: (2020)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

TIGIT reverses IFN-α-promoted Th1-like Tregs via in-sequence effects dependent on STAT4
por: Yu, Shihan, et al.
Publicado: (2023)

Treg in CNS autoimmune disease
por: Anderton, Stephen M
Publicado: (2012)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma
por: Raphael, Itay, et al.
Publicado: (2021)

Experimental autoimmune uveitis and other animal models of uveitis: An update
por: Bansal, Svati, et al.
Publicado: (2015)

Immunotherapeutic strategies in autoimmune uveitis
por: Papotto, Pedro Henrique, et al.
Publicado: (2014)

Autoimmune and autoinflammatory mechanisms in uveitis
por: Lee, Richard W., et al.
Publicado: (2014)

Helios but not CD226, TIGIT and Foxp3 is a Potential Marker for CD4(+) Treg Cells in Patients with Rheumatoid Arthritis
por: Yang, Mengru, et al.
Publicado: (2019)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
por: Mu, Songlin, et al.
Publicado: (2022)

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
por: Zhong, Zhenwei, et al.
Publicado: (2022)

Induction of antigen-specific Treg cells in treating autoimmune uveitis via bystander suppressive pathways without compromising anti-tumor immunity
por: Chen, Zilin, et al.
Publicado: (2021)

Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT
por: Gilbert, Rose M., et al.
Publicado: (2018)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2022)

Parental Uveitis Influences Offspring With an Increased Susceptibility to the Experimental Autoimmune Uveitis
por: Yin, Guangnian, et al.
Publicado: (2020)

MicroRNAs in the regulation of Th17/Treg homeostasis and their potential role in uveitis
por: Tang, Fen, et al.
Publicado: (2022)

Uveitis as a Predictor of Predisposition to Autoimmunity
por: Leibowitz, Jillian A, et al.
Publicado: (2020)

Apolipoprotein A1 Modulates Teff/Treg Balance Through Scavenger Receptor Class B Type I-Dependent Mechanisms in Experimental Autoimmune Uveitis
por: Huang, Haixiang, et al.
Publicado: (2022)

Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
por: Gianchecchi, Elena, et al.
Publicado: (2018)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
por: Peng, Hui, et al.
Publicado: (2022)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
por: Simon, Sylvain, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c2t0so3pntgaqt490ees80vnak